AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
286.01
-6.81 (-2.33%)
At close: Nov 18, 2026, 4:00 PM EST
285.95
-0.06 (-0.02%)
After-hours: Nov 18, 2026, 7:57 PM EST
AbbVie Revenue
AbbVie had revenue of $17.40B in the quarter ending September 30, 2026, with 10.32% growth. This brings the company's total for the last twelve months to $66.01B, up 10.68% year-over-year. In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth. That makes AbbVie the 184th largest company in the world by revenue and 75th in the United States.
Revenue (ttm)
$66.01B
Revenue Growth
+10.68%
P/S Ratio
7.66
Revenue / Employee
$1,158,140
Employees
57,000
Market Cap
505.56B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full AbbVie breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Eli Lilly and Company | 86.46B |
| Merck & Co. | 67.38B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
ABBV News
- 9 hours ago - Worried investors are paying up for these stocks — some with up to 49% upside, analysts say - Market Watch
- 13 hours ago - AbbVie price target raised to $349 from $303 at Piper Sandler - TheFly
- 2 days ago - AbbVie put volume heavy and directionally bearish - TheFly
- 2 days ago - AbbVie price target raised to $335 from $325 at Barclays - TheFly
- 10 days ago - AbbVie’s Allergan Aesthetics announces results from Harmony In Diversity, Halo - TheFly
- 10 days ago - Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications - PRNewsWire
- 12 days ago - Healthcare Stocks Fall as Market Rout Spreads - WSJ
- 14 days ago - AbbVie price target raised to $315 from $285 at Freedom Broker - TheFly